To join this case, fill out the form below
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Renovacor, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Renovacor, Inc. (“Renovacor” or the “Company”) (NYSE:RCOR), in connection with the proposed acquisition of the Company by Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals”) (NASDAQ: RCKT).  Under the terms of the merger agreement, the Company’s shareholders will receive 0.1676 shares of Rocket Pharmaceuticals common stock for each Renovacor share owned, representing implied per-share merger consideration of approximately $2.34 based upon Rocket Pharmaceuticals’ September 19, 2022 closing price of $13.97.

Weiss Law is investigating whether (i) Renovacor’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Renovacor’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.